A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

NCT01469130 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: MEK162

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer